Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Chengdu Lingtai Krypton Biotechnology

Request full access

LncRNA-based therapies for traditionally undruggable targets

ChinaFounded 2021Biotech & Life Sciences

About Chengdu Lingtai Krypton Biotechnology

Chengdu Lingtai Krypton Biotechnology (lncTAC), founded in 2021, is a clinical-stage biotechnology company focused on developing innovative nucleic acid drugs based on long non-coding RNA (lncRNA). The company's name, lncTAC, is an acronym for its core "lncRNA-based Targeting Chimera" technology platform.

The founding team combines deep scientific expertise with extensive pharmaceutical industry experience. Founder and Chairman, Professor Xu Song, is a pioneering scientist in the lncRNA field with 20 years of research experience, a PhD from Peking Union Medical College, and postdoctoral work at Yale University. He is joined by co-founder and CEO, Dr. Lihua Ding, who brings over 30 years of senior management experience from multinational and domestic pharmaceutical companies, and co-founder Professor Chong Qin, an expert in PROTAC and one of the inventors of the lncTAC® technology.

The company has developed two core proprietary technology platforms: lncTAC® and UNAST®. The lncTAC® platform utilizes lncRNA-mediated targeting chimera technology to address previously "undruggable" targets. The UNAST® platform was created to solve the critical challenges of nucleic acid drug instability and delivery. Together, these platforms form the foundation for a rich pipeline of over 20 innovative products. These drug candidates target a range of refractory diseases, including cardiovascular and cerebrovascular diseases, neurodegenerative conditions like Alzheimer's and Parkinson's, and various cancers such as pancreatic, lung, and colorectal cancer.

LncTAC's business model focuses on research and development, with a commercialization strategy centered on out-licensing and forming in-depth collaborations with domestic and multinational corporations for market development. The company has successfully raised significant capital, including a Pre-A round of ¥100 million in August 2023, to advance its pipeline through preclinical stages and expand its research teams.

Source: Dealroom company data

At a glance

Status
Operational
Employees
52
Open positions
None listed
Dealroom signal
25.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jun 2026 — — Legend Capital · Pan-Lin Asset Management · River Head Capital · Beijing Huafang Investment ↗
SEED✓Equity / VC Oct 2023 $14M $55M Legend Capital · China Medical System Holdings · Guosheng Capital · Firefly Haoyue ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Chengdu Lingtai Krypton Biotechnology website traffic

Latest recorded traffic for Chengdu Lingtai Krypton Biotechnology is 530 monthly website visits, up 253.3% over the last three months.

Latest monthly visits530 3-month web change+253.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Chengdu Lingtai Krypton Biotechnology in its local ecosystem

Live from Dealroom

The Chengdu Lingtai Krypton Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • Legend Capital
  • China Medical System Holdings
  • Guosheng Capital
  • Firefly Haoyue

Series A4 investors entered at this stage

  • Pan-Lin Asset Management
  • River Head Capital
  • Beijing Huafang Investment
  • IMEIK Technology

Other known investors1 additional known investor

  • Bayer Co.Lab
Employees 52 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Chengdu Lingtai Krypton Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Chengdu Lingtai Krypton Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.